Alkermes Plc (ALKS)

NASDAQ
31.48
+0.90(+2.94%)
After Hours
31.50
+0.02(+0.06%)
- Real-time Data
  • Volume:
    1,163,202
  • Day's Range:
    30.59 - 31.49
  • 52 wk Range:
    21.75 - 33.71
Earnings results expected in 8 days

Alkermes Plc will announce its quarterly financial results in 8 days. Traders should take this into account as the share price often fluctuates around this time period.

ALKS Overview

Prev. Close
30.58
Day's Range
30.59-31.49
Revenue
1.12B
Open
30.71
52 wk Range
21.75-33.71
EPS
-1
Volume
1,163,202
Market Cap
5.23B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,319,590
P/E Ratio
-31.36
Beta
0.61
1-Year Change
7.15%
Shares Outstanding
166,121,384
Next Earnings Date
Jul 27, 2023
What is your sentiment on Alkermes Plc?
or
Market is currently closed. Voting is open during market hours.

Alkermes Plc Company Profile

Alkermes Plc Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • Dublin-based Alkermes may not be one of the top biotech stocks that stand out to U.S. investors, open ur eyes ppl
    0
    • Any recommendation to buy?
      0
      • Why again going down ??
        0
        • No reason to go up for next 3 months. Buy at 19 -19.10..stay long
          0
      • Why again getting into sh... somebody there?
        0